Patents by Inventor Judith Rosina Van Beijnum

Judith Rosina Van Beijnum has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10023868
    Abstract: The invention relates to the diagnostic and therapeutic uses of a miRNA molecule, an equivalent or a source thereof in a disease and condition associated with neo-angiogenesis.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: July 17, 2018
    Assignee: INTERNA TECHNOLOGIES B.V.
    Inventors: Sanne Weijzen, Roeland Quirinus Jozef Schaapveld, Meriem Bourajjaj, Rick Jan Van Haastert, Arjan Willem Griffioen, Judith Rosina Van Beijnum, Edwin Pieter Johan Gerard Cuppen, Eugene Berezikov, Andreas Alphons Franciscus Ludovicus Van Puijenbroek, Willemijn Maria Gommans, Negar Babae, Petronella Innocentia Van Noort
  • Publication number: 20140005251
    Abstract: The invention relates to the diagnostic and therapeutic uses of a miRNA molecule, an equivalent or a source thereof in a disease and condition associated with neo-angiogenesis.
    Type: Application
    Filed: July 2, 2013
    Publication date: January 2, 2014
    Applicant: InteRNA Technologies B.V.
    Inventors: Sanne WEIJZEN, Roeland Quirinus Jozef SCHAAPVELD, Meriem BOURAJJAJ, Rick Jan VAN HAASTERT, Arjan Willem GRIFFIOEN, Judith Rosina VAN BEIJNUM, Edwin Pieter Johan Gerard CUPPEN, Eugene BEREZIKOV, Andreas Alphons Franciscus Ludovicus VAN PUIJENBROEK, Willemijn Maria GOMMANS, Negar BABAE, Petronella Innocentia VAN NOORT
  • Publication number: 20110229483
    Abstract: Crucial to designing anti-angiogenic and vascular targeting approaches is the identification of specific target molecules. We compared transcriptional profiles of tumor endothelial cells with that of normal resting endothelial cells, normal but angiogenically activated placental endothelial cells, and cultured endothelial cells. Although the majority of transcripts were classified as general angiogenesis markers, we identified 17 genes that show specific overexpression in tumor endothelium. Antibody targeting of four cell-surface expressed or secreted products (vimentin, CD59, HMGB1 and IGFBP7) inhibited angiogenesis in vitro and in vivo. Finally, targeting endothelial vimentin in a mouse tumor model significantly inhibited tumor growth and reduced microvessel density. Our results demonstrate the utility of the identification and subsequent targeting of specific tumor endothelial markers for anticancer therapy.
    Type: Application
    Filed: April 22, 2011
    Publication date: September 22, 2011
    Applicant: Universiteit Maastricht
    Inventors: Arjan Willem Griffioen, Judith Rosina Van Beijnum
  • Publication number: 20090035312
    Abstract: Methods of identifying specific target molecules for design of anti-angiogenic and vascular targeting approaches are disclosed. Transcriptional profiles of tumor endothelial cells were compared with that of normal resting endothelial cells, normal but angiogenically activated placental endothelial cells, and cultured endothelial cells. Although the majority of transcripts were classified as general angiogenesis markers, 17 genes were identified that show specific overexpression in tumor endothelium. Antibody targeting of four cell-surface expressed or secreted products (vimentin, CD59, HMGB1 and IGFBP7) inhibited angiogenesis in vitro and in vivo. Finally, targeting endothelial vimentin in a mouse tumor model significantly inhibited tumor growth and reduced microvessel density. The results demonstrate the utility of the identification and subsequent targeting of specific tumor endothelial markers for anticancer therapy.
    Type: Application
    Filed: September 29, 2006
    Publication date: February 5, 2009
    Applicant: Universiteit Maastricht
    Inventors: Arjan Willem Griffioen, Judith Rosina Van Beijnum